ICOTYDE approved, rusfertide on track for Q3 decision; Takeda opt-out triggers $475M inflow

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  ICOTYDE received FDA approval in March 2026 for moderate-to-severe plaque psoriasis, triggering a $50M milestone from JNJ and positioning the company to receive 6-10% royalties on net sales (7.25% weighted-average rate on first $4B annually).

  MD&A: ICOTYDE FDA approval verify on EDGAR →
• high

  Rusfertide NDA granted Priority Review with Q3 2026 PDUFA date; Takeda expects second-half launch if approved. Company exercised opt-out right in April 2026, converting from 50/50 U.S. profit-share to worldwide royalty structure and triggering $400M in opt-out payments plus $75M approval milestone, with tiered royalties of 14-29% on worldwide sales.

  MD&A: rusfertide NDA & Takeda opt-out verify on EDGAR →
• high

  Two obesity development candidates nominated: PN-477 (triple GLP-1/GIP/GCG agonist, Phase 1 expected mid-2026) and PN-458 (dual GLP-1/GIP agonist, IND-enabling studies ongoing), both with oral and subcutaneous formulation options, establishing entry into the large obesity market.

  MD&A: obesity program development verify on EDGAR →